secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oncotelic Therapeutics, Inc. (OTLC)
CIK:        0000908259
Form:       8-K
Filed at:   2021-11-24T23:59:59+00:00
Accession:  0001493152-21-029720
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02
LLM model:  deepseek-v4-flash:cloud@v2

Oncotelic reports Q3 net loss of $1.9M; provides JV, license, and clinical updates
--------------------------------------------------------------------------------

- Net loss: $1.86M (($0.00)/share) vs $1.99M (($0.02)/share) in Q3 2020; operating expenses rose to $1.8M.
- Secured $1.5M convertible note from GMP in Sep 2021 plus $0.5M in Oct 2021; JV with GMP for product portfolio at 35% stake.
- Exclusive license from Autotelic for patents; milestones up to $50M and 15% royalties on net sales.
- OT-101/IL-2 combo safety cohort completed; dose escalation above 140 mg/m² ongoing.
- OT-101 COVID-19 trial data locked; showed 4.5% mortality (OT-101) vs 20% placebo and improved overall survival.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/908259/000149315221029720/0001493152-21-029720-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/908259/000149315221029720/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-21-029720

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer